Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
Legros L, Slama B, Karsenti JM, Vey N, Natarajan-Amé S, Watel E, Richard B, Bouabdallah K, Mannone L, Benchetrit M, Touitou I, Huault S, Durivault J, Ambroseti D, Hueber AO, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies.
Legros L, et al. Among authors: huault s.
Ann Hematol. 2012 Jan;91(1):39-46. doi: 10.1007/s00277-011-1242-z. Epub 2011 May 7.
Ann Hematol. 2012.
PMID: 21553011
Clinical Trial.